Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III BAT1406 versus Humira in active ankylosing spondylitis
ChiCTR1900026772Phase 3Completed
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of qletli in ankylosing spondylitis (AS) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: ASAS20 response at week 12. Started Dec 2016; status: completed.
02
Drugs
qletli
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR1900026772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026772.